CCME Global Ltd vs TORRENT PHARMACEUTICALS L

A side-by-side comparison of CCME Global Ltd (CCME) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, TORRENT PHARMACEUTICALS L leads CCME vs TORNTPHARM on 9 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation22
  • Profitability04
  • Growth· not comparable—
  • Size & financial health13

Valuation

Even

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

-150.40
P/E ratio
71.32
3.23
P/B ratio
22.29
0.00%
Dividend yield
0.77%
₹-0.16
EPS
₹63.92

Profitability

TORNTPHARM takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

-1.78%
Return on equity
25.78%
-1.78%
Return on capital
13.91%
4.65%
EBITDA margin
32.61%
0.00%
Net margin
15.29%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

—
Revenue CAGR (3Y) even
13.27%
—
Profit CAGR (3Y) even
19.75%

Size & financial health

TORNTPHARM takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹159 Cr
Market cap
₹1.73L Cr
₹0 Cr
Revenue
₹13,980 Cr
₹-1 Cr
Net profit
₹2,138 Cr
0.00
Debt / equity
1.79
CCME Global Ltd
  • + ["Company is almost debt free."]
  • − ["Company has a low return on equity of -2.0% over last 3 years.", "Company reported a net loss of ₹1 Cr in its latest financial year."]
TORRENT PHARMACEUTICALS L
  • + ["Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 67.6%"]
  • − ["Stock is trading at 20.67 times its book value", "Company has a high debt to equity ratio of 1.79."]
CCME Global Ltd full analysis TORRENT PHARMACEUTICALS L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.